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Massachusetts Selected to Partner in Biopharmaceutical Manufacturing 
Innovation 
Public-private partnership will develop and commercialize new advanced 
manufacturing technologies, and train a skilled workforce 
 
BOSTON - Today the Baker-Polito Administration is pleased to announce that 
Massachusetts will be a partner in the nation’s first manufacturing innovation 
institute in biopharmaceutical manufacturing. The biopharmaceutical manufacturing 
innovation institute is the sixth Manufacturing USA project secured under the Baker-
Polito Administration 
 
The $250 million biopharmaceutical innovation institute is a national public-private 
partnership, awarded through Manufacturing USA, a federally-authorized network of 
manufacturing innovation institutes. Federal matching funds for the manufacturing 
innovation institute will be provided by the US Department of Commerce’s National 
Institute of Standards and Technology. The University of Delaware convened this 
Manufacturing USA team. 
 
Massachusetts will anchor the northeastern node for the biopharmaceutical 
manufacturing project, which will be known as the National Institute for Innovation 
in Manufacturing Biopharmaceuticals (NIIMBL). The NIIMBL project will be led 
regionally by a consortium of small, medium, and large biopharmaceutical industry 
partners from across the supply chain, along with the Massachusetts Institute of 
Technology (MIT), Quincy College, UMass Lowell, UMass Medical School, and the 
Worcester Polytechnic Institute (WPI).  
 
  
The Commonwealth is supporting NIIMBL’s collaborative research and development, 
and workforce training efforts, through a five-year, $20 million commitment from the 
Massachusetts Life Sciences Center (MLSC). The Commonwealth’s matching 
contribution leverages $70 million in federal funds, awarded to the national project, 
and additional matching funds from private sector participants.  
 
“Massachusetts leads the nation in the development and deployment of advanced 
manufacturing technologies, and this new biopharmaceutical manufacturing 
innovation institute will ensure that our globally competitive life sciences cluster 
continues to deliver cutting-edge therapies, while providing quality manufacturing 
jobs to the citizens of Massachusetts,” said Governor Charlie Baker. “NIIMBL 
continues our administration’s substantial investment in public-private research 
partnerships that open new advanced manufacturing pathways for workers across 
Massachusetts. We look forward to collaborating with our partners in the federal 
government, academia, and the private sector, as we continue to build a foundation 
for dynamic economic growth.”  
 
“Our administration is harnessing advanced manufacturing and workforce 
development to build prosperity across Massachusetts, and NIIMBL advances these 
efforts in meaningful ways,” said Lieutenant Governor Karyn Polito. “By 
strengthening the ties between academic research institutions, commercial 
biopharmaceutical research and development efforts, and the manufacturing 
community, we will create new capacity to manufacture modern biopharmaceutical 
therapies in Massachusetts, and continue to broaden the reach of the life sciences 
cluster throughout the Commonwealth.”  
 
A shift in the delivery of medical treatments, from powder-based medicines based on 
chemistry and manufactured in large batches, to biologics, cell therapies, and gene 
therapies, presents new challenges for the manufacturing of biopharmaceutical 
treatments at scale. The National Institute for Innovation in Manufacturing 
Biopharmaceuticals is a public-private partnership that seeks to solve challenges 
related to the production, testing, and regulation of new treatments.  
 
NIIMBL is a process innovation effort that aims to reduce the risks associated with 
manufacturing new therapies, improve efficiency in order to deliver new therapies to 
patients more quickly and at lower cost, and increase the quality and safety of new 
biopharmaceutical products.  
 
The project will also train an advanced manufacturing workforce, capable of working 
in new biopharmaceutical manufacturing technologies.  
 
“Being selected as the Northeast node for the National Institute for Innovation in 
Biopharmaceutical Manufacturing, and the federal funding that comes with it, will 
further strengthen Massachusetts’s position as the world’s leading ecosystem for 
drug development, from discovery, right through to commercialization and 
fabrication,” said Travis McCready, President and CEO of the Massachusetts Life 
Sciences Center. “This Institute will build connections between our biomanufacturing 
innovators in industry and academia, and will connect the innovation going on in 
manufacturing with the innovation going on in the lab. This will translate into 
technical innovations to improve the biomanufacturing process, allowing for new 
drugs to reach and help patients more efficiently, and at lower cost.” 
 
“Biopharmaceutical manufacturing innovation at MIT and in our region is reflected by 
the many small and large companies -- and talented faculty and students --- that have 
come out of such research,” said MIT Provost Martin Schmidt. “Those companies 
have settled in Massachusetts to be part of the growing innovation ecosystem 
anchored in Kendall Square but linked to vibrant regions across the entire 
Commonwealth. MIT looks forward to continuing to be a strong partner in NIIMBL's 
national efforts to de-risk manufacturing technologies for new biologic therapies, and 
to educate and train the future workforce of these companies.” 
 
“The University of Massachusetts is proud to leverage the Massachusetts 
BioManufacturing Center (MBMC) at Lowell and MassBiologics in Boston and Fall 
River as part of the NIIMBL effort,” said UMass President Marty Meehan. “UMass 
has years of experience assisting biotechnology companies in developing cGMP 
compliant manufacturing processes and in producing FDA-licensed therapeutics, 
offering solutions that improve productivity, quality and cost. NIIMBL reflects our 
commitment to expand these public-private partnerships that contribute to the 
research, innovation, economic development and workforce development needs of 
the Commonwealth.” 
 
“WPI was founded more than 150 years ago to support education and workforce 
development during the industrial revolution, and we look forward to driving 
innovation, career development, and other techniques to support 21st century 
biopharmaceutical manufacturing initiatives,” said WPI President Laurie Leshin. “For 
the past decade, WPI has been home to three bioscience facilities that are 
instrumental to education and innovation in biomanufacturing. We are committed to 
making those facilities -- the Life Science and Bioengineering Center, the Bioprocess 
Lab, and the Biomanufacturing Education and Training Center -- indispensable 
resources for organizations seeking competitive advantages in a global 
manufacturing economy.” 
 
“Quincy College is proud to comprehensively teach the laboratory and critical 
thinking skills necessary to enter the growing biomanufacturing industry in 
Massachusetts and beyond,” said Bruce Van Dyke, Chair of the Biotechnology and 
Compliance Program at Quincy College. “Through lectures, seminars, and over 450 
hours of hands-on laboratory experience, students earn an Associate of Science or 
Certificate in Biotechnology and Good Manufacturing Practice, and are fully trained 
to begin working in the biomanufacturing industry at entry-level positions. As a 
partner in the NIIMBL Project, our role would be to train individuals to fill 
biopharmaceutical manufacturing positions in the local workforce.” 
 
Manufacturing USA, formerly known as the National Network for Manufacturing 
Institutes, is a network of competitively awarded public-private innovation institutes. 
Manufacturing USA seeks to spur research into cutting-edge technologies that can be 
applied to advanced manufacturing processes. Bidders frequently form teams of 
universities across different states, with regional nodes supporting the lead bidder. 
The federal awards are leveraged several times over through a series of state and 
industry matches. 
 
Massachusetts is convening a national effort to develop revolutionary fibers and 
textiles, and the state is a participant in regional manufacturing innovation institute 
nodes in photonics, flexible hybrid electronics, smart manufacturing, and rapid 
process intensification.  
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